Epilepsy and polycystic ovary syndrome: Where is the link?

Neurological Sciences

Volumn 27, Issue 4, 2006, Pages 221-230

  Bilo, Leda ^a   Meo, R ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Neurology Outpatients Service   (Italy)

Author keywords

Epilepsy; Hyperandrogenism; Menstrual irregularities; Polycystic ovaries; Polycystic ovary syndrome; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GONADORELIN; LITHIUM; LUTEINIZING HORMONE; VALPROIC ACID;

BIPOLAR DISORDER; DISEASE ASSOCIATION; ENDOCRINE DISEASE; EPILEPSY; FEMALE; HUMAN; HYPERANDROGENISM; HYPOTHALAMUS; HYPOTHESIS; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PREVALENCE; REGULATORY MECHANISM; REPRODUCTION; REVIEW;

EPILEPSY; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MODELS, BIOLOGICAL; POLYCYSTIC OVARY SYNDROME; VALPROIC ACID;

EID: 33749046114     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-006-0675-y     Document Type: Review

References (66)

1. Spratling W (1904) Epilepsy and its treatment. Saunders WB, New York
2. Herzog AG, Seibel MM, Schomer D et al (1984) Temporal lobe epilepsy: An extrahypothalamic pathogenesis for polycystic ovary syndrome? Neurology 34:1389-1393
3. Herzog AG, Seibel MM, Schomer D et al (1986) Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 43:341-346
4. Bilo L, Meo R, Nappi C et al (1988) Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 29:612-619
5. Isojarvi JIT, Laatikainen TJ, Pakarinen AJ et al (1993) Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 329:1383-1388
6. Meo R, Bilo L (2003) Polycystic ovary syndrome and epilepsy: A review of the evidence. Drugs 63:1185-1227
7. Zawadzki J, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome. Towards a rational approach. In: Dunaif A, Givens J, Haseltine F, Merriam GR (eds) Polycystic ovary syndrome. Blackwell Scientific, Boston
8. Taylor AE (1998) Polycystic ovary syndrome. Endocrinol Metab Clin North Am 27:877-902
9. Taylor AE (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41-47
10. Azziz R (2005) Diagnostic criteria for polycystic ovary syndrome: A reappraisal. Fertil Steril 83:1343-1346
11. Franks S (2006) Diagnosis of polycystic ovary syndrome: In defence of the Rotterdam Criteria. J Clin Endocrinol Metab 91:786-789
12. Azziz R (2006) Controversy in clinical endocrinology: Diagnosis of polycystic ovarian syndrome: The Rotterdam criteria are premature. J Clin Endocrinol Metab 91:781-785
13. Azziz R,Woods KS, Reyna R et al (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745-2749
14. Asuncion M, Calvo RM, San Millan JL et al (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85:2434-2438
15. Diamanti-Kandarakis E, Kouli CR, Bergiele AT et al (1999) A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile. J Clin Endocrinol Metab 84:4006-4011
16. Knobil E (1988) The neuroendocrine control of ovulation. Hum Reprod 3:469-72
17. Dana-Haeri J, Trimble M, Oxley J (1983) Prolactin and gonadotropin changes following generalised and partial seizures. J Neurol Neurosurg Psychiatry 46:331-335
18. Dana-Haeri J, Trimble MR (1984) Prolactin and gonadotropin changes following partial seizures in epileptic patients with and without psychopathology. Biol Psychiatry 19:329-336
19. Mattson RH, Toftness BR, Cramer JA (1987) Postictal pituitary hormonal changes. Neurology 37[Suppl 1]:100-101
20. Bilo L, Meo R, Valentino R et al (1991) Abnormal pattern of luteinizing hormone pulsatility in women with epilepsy. Fertil Steril 55:705-711
21. Drislane FW, Coleman AE, Schomer DL et al (1994) Altered pulsatile secretion of luteinizing hormone in women with epilepsy. Neurology 44:306-310
22. Morrell MJ, Seale CG, Hamdy S, Giudice L (1998) Luteinizing hormone pulsatility in women with epilepsy treated with AED monotherapy. Epilepsia 39[Suppl 6]:221
23. Morrell MJ, Sauer MV, Giudice L et al (2000) Pituitary gonadotropin function in women with epilepsy. Epilepsia 41[Suppl 7]:247
24. Quigg M, Kiely JM, Shneker B et al (2002) Chronic elevation of pulsatile luteinizing hormone secretion and acute depression of postictal pulse rate and orderliness in temporal lobe epilepsy. Epilepsia 42[Suppl 7]:118-119
25. Meo R, Bilo L, Nappi C et al (1993) Derangement of the hypothalamic GnRH pulse generator in women with epilepsy. Seizure 2:241-252
26. Nappi C, Meo R, Di Carlo C et al (1994) Reduced fertility and neuroendocrine dysfunction in women with epilepsy. Gynecol Endocrinol 8:133-145
27. Sackellares JC, Crosby C (1980) Long-term efficacy of valproic acid (VPA) in the treatment of absence seizures. Neurology 30:420
28. Margraf JW, Dreifuss FE (1981) Amenorrhea following initiation of therapy with valproic acid. Neurology 31:151
29. de Krom MCTFM, Hoppener RJEA, Beukers E (1985) Adverse reactions of sodium valproate: Secondary amenorrhea and weight gain. Clin Neurol Neurosurg 81:66
30. Maggio B, Giampietro L (1987) Su alcuni effetti endocrinologici del VPA. Bollettino della Lega Italiana contro l'Epilessia 58/59:205-206
31. Jones TH (1991) Sodium valproate-induced menstrual disturbances in young women. Horm Res 35:82-85
32. Isojarvi JIT, Laatikainen TJ, Knip M et al (1996) Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 39:579-584
33. Isojarvi JIT, Tauboll E, Pakarinen AJ et al (2001) Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 111:290-296
34. Chappell KA, Markowitz JS, Jackson CW (1999) Is valproate pharmacotherapy associated with polycystic ovaries? Ann Pharmacother 33:1211-1216
35. Nelson-Degrave VL, Wickenheisser JK, Cockrell JE et al (2004) Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 145:799-808
36. Wood JR, Nelson-Degrave VL, Jansen E et al (2005) Valproate-induced alterations in human theca cell gene expression: Clues to the association between valproate use and metabolic side effects. Physiol Genomics 20:233-243
37. Faur N, Prat X, Bastide A, Lemay A (1989) Assessment of ovaries by magnetic resonance imaging in patients presenting with polycystic ovarian syndrome. Hum Reprod 4:468-472
38. Herzog AG, Schachter SC (2001) Valproate and the polycystic ovary syndrome: Final thoughts. Epilepsia 42:311-315
39. Joffe H, Taylor AE, Hall JE (2001) Polycystic ovarian syndrome - relationship to epilepsy and antiepileptic drug therapy. J Clin Endocrinol Metab 86:2946-2949
40. Murialdo G, Galimberti CA, Magri F et al (1997) Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest 20:519-526
41. Murialdo G, Galimberti CA, Gianelli MV et al (1998) Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 21:52-58
42. Bauer J, Jarre A, Klingmuller D, Elger CE (2000) Polycystic ovary syndrome in patients with focal epilepsy: A study in 93 women. Epilepsy Res 41:167
43. Bilo L, Meo R, Valentino R et al (2001) Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab 86:2950-2956
44. Stephen LJ, Kwan P, Shapiro D et al (2001) Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 42:1002-1006
45. Luef G, Abraham I, Trinka E et al (2002) Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Res 48:91-102
46. Luef G, Abraham I, Haslinger M et al (2002) Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. J Neurol 249:835-841
47. Skierska E, Leszczynska-Bystrzanowska J, Gajewski AK (1996) [Risk analysis of menstrual disorders in young women from urban population]. Przegl Epidemiol 50:467-474
48. Laidlaw J (1956) Catamenial epilepsy. Lancet 2:1235-1237
49. Logothetis J, Harner R, Morrell F, Torres F (1959) The role of estrogens in catamenial exacerbations of epilepsy. Neurology 9:352-360
50. Trampuz V, Dimitrijevic M, Kryzanovski J (1975) Ulga epilepsije u patogenezi disfunkcije ovarija. Neuropsihijatrija 23:179-183
51. Backstrom T (1976) Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol Scand 54:321-347
52. Rosciszewska D, Dudkiewicz J, Blecharz A (1976) Changes in cytohormonal cervical swabs in epileptic women. Neurol Neurochir Pol 10:255-259
53. Jensen I, Vaernet K (1977) Temporal lobe epilepsy: Follow-up investigation of 74 temporal lobe resected patients. Acta Neurochir 37:173-200
54. Mattson RH, Kamer JA, Caldwell BV, Cramer JA (1981) Seizure frequency and the menstrual cycle: A clinical study. Epilepsia 22:242
55. Khatami R, Henrich W, Bauer M et al (2000) The significance of polycystic ovaries in women with epilepsy under treatment with antiepileptic drugs: Preliminary results of a prospective observational study. Epilepsia 41:S143
56. Betts T, Yarrow H, Dutton N et al (2003) A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of women without epilepsy. Seizure 12:323-329
57. O'Donovan C, Graves J, Kusumakar V (1999) Prevalence rates of self-reported menstrual abnormalities and clinical hyperandrogenism of women taking divalproex for bipolar mood disorder. Proceedings Third Conference on Bipolar Disorder (Pittsburgh, 17-19 June 1999)
58. O'Donovan C, Kusumakar V, Graves GR, Bird DC (2002) Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 63:322-330
59. Joffe H, Hall JE, Cohen LS et al (2003) A putative relationship between valproic acid and polycystic ovarian syndrome: Implications for treatment of women with seizure and bipolar disorders. Harv Rev Psychiatry 11:99-108
60. Rasgon NL, Altshuler LL, Fairbanks L et al (2005) Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 7:246-259
61. Rasgon NL, Altshuler LL, Guideman D et al (2000) Medication status and polycystic ovary syndrome in women with bipolar disorder: A preliminary report. J Clin Psychiatry 61:173-178
62. Rasgon NL, Reynolds MF, Elman S et al (2005) Longitudinal evaluation of reproductive function in women treated for bipolar disorder. J Affect Disord 89:217-225
63. McIntyre RS, Mancini DA, McCann S et al (2003) Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord 5:28-35
64. Akdeniz F, Taneli F, Noyan A et al (2003) Valproate-associated reproductive and metabolic abnormalities: Are epileptic women at greater risk than bipolar women? Prog Neuropsychopharmacol Biol Psychiatry 27:115-121
65. Joffe H, Cohen LS, Suppes T et al (2006) Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 59:1078-1086
66. Herzog AG (2006) Menstrual disorders in women with epilepsy. Neurology 66[Suppl 3]:S23-S28